Effect of Naringenin and Beta Carotene on Energy Expenditure
Overview
This study is designed to test the effects of the combination of naringenin (from an extract of sweet oranges) and beta carotene on energy expenditure and glucose metabolism in a single human subject.
Full Title of Study: “Case Study to Evaluate the Safety and Effect on Energy Expenditure of Naringenin and Beta Carotene”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Other
- Masking: None (Open Label)
- Study Primary Completion Date: June 16, 2021
Detailed Description
The subject will be treated for 8 weeks with the combination of naringenin + beta carotene. We will conduct the following assessments before the treatment and at the end of eight weeks. 1. Resting metabolic rate 2. Oral glucose tolerance test with glucose and insulin 3. Ambulatory blood pressure 4. Recording of adverse events 5. Body weight
Interventions
- Dietary Supplement: naringenin and beta carotene
- Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks
Arms, Groups and Cohorts
- Experimental: Naringenin + Beta carotene
- Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day
Clinical Trial Outcome Measures
Primary Measures
- Energy expenditure
- Time Frame: Five hours
- Ventilated hood
- Incidence of Treatment-Emergent Adverse Events
- Time Frame: Eight weeks
- Adverse events
Secondary Measures
- Glucose metabolism
- Time Frame: Three hours
- Oral glucose tolerance test with insulin
- Blood pressure
- Time Frame: 24 hours
- Ambulatory
- Body weight
- Time Frame: 16 weeks
- Measurement of body weight
Participating in This Clinical Trial
Inclusion Criteria
- Fasting blood glucose < 200mg/dL Exclusion Criteria:
- Known allergy to citrus fruits
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Pennington Biomedical Research Center
- Provider of Information About this Clinical Study
- Principal Investigator: Frank Greenway, Chief Medical Officer – Pennington Biomedical Research Center
- Overall Official(s)
- Frank L Greenway, M.D., Principal Investigator, Pennington Biomedical Research Center
References
Murugesan N, Woodard K, Ramaraju R, Greenway FL, Coulter AA, Rebello CJ. Naringenin Increases Insulin Sensitivity and Metabolic Rate: A Case Study. J Med Food. 2020 Mar;23(3):343-348. doi: 10.1089/jmf.2019.0216. Epub 2019 Oct 31.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.